361 Capital’s Collegium Pharmaceutical COLL Stock Holding History

361 Capital’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$661K	Sell	37,779 -5,884	-13%	-$115K	0.31%	178
2020 Q1	$713K	Buy	+43,663	New	+$901K	0.32%	144
2018 Q2	–	Sell	-57,982	Closed	-$1.48M	–	333
2018 Q1	$1.48M	Buy	+57,982	New	+$1.38M	0.37%	134

Other funds holding COLL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

361 Capital's COLL Position: Q2 2020 in Review

361 Capital reduced its Collegium Pharmaceutical (COLL) stake by 13% in Q2 2020, selling an estimated $115K and leaving 37,779 shares worth $661K. The position accounts for 0.31% of the portfolio, ranked #178.

361 Capital first reported a position in COLL in Q1 2018 and has held it in 3 quarters since. The position peaked at $1.48M in Q1 2018. 150 funds tracked by Wall St. Rank hold COLL as of Q2 2020.

361 Capital held 37,779 shares of Collegium Pharmaceutical worth $661K as of Q2 2020.
361 Capital sold 5,884 Collegium Pharmaceutical shares in Q2 2020, an estimated $115K.
Collegium Pharmaceutical made up 0.31% of 361 Capital's portfolio in Q2 2020, its #178 holding.
361 Capital first reported a position in Collegium Pharmaceutical in Q1 2018 and has held it in 3 quarters since.
361 Capital's Collegium Pharmaceutical position peaked at $1.48M in Q1 2018.
150 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.